Diagnosis and treatment system for "reward deficiency syndrome" (RDS) and related behaviors

Abstract

The present invention relates to a kit and an intravenously administrable preparation, both with a signal transmitter precursor, an enhancer of precursor uptake, and an inhibitor of neurotransmitter reuptake or signal transmitter catabolism. The kit also contains an appropriate swab for obtaining oral cells suitable for allelic analysis. The intravenous formulation contains similar materials and, in some cases, ethanol. Either the kit composition or the intravenous formulation may be used as guided by a subjects allelic analysis. Collections of particular alleles, especially those relating to neural system are comprehensible in terms of likelihood of success in the administration of an intraveinous formulation or ingestion of components of the subject kit.

1 . An intravenous formulation comprising at least one pharmaceutically acceptable carrier and consisting of a signal transmitter precursor, an enhancer of precursors uptake, and an inhibitor of neurotransmitter re-uptake or signal-transmitter catabolism.  
   
   
       2 . The intravenous formulation of  claim 1  wherein an allelic analysis of a subject predicts likelihood of positive effects of a subjects intake of the formulation in effective amounts.  
   
   
       3 . The intravenous formulation of  claim 1  wherein the enhancer is a chromium salt.  
   
   
       4 . The intravenous formulation of  claim 1  wherein the enhancer is at least one of ethanol or calcium.  
   
   
       5 . The intravenous formulation of  claim 1  wherein the inhibitor is D Phenylalanine or DL Phenylalanine.  
   
   
       6 . The intravenous formulation of  claim 1  where the signal transmitter is a neurotransmitter, a peptidyl transmitter or opiate, nitric oxide, or other secondary intercellular messenger.  
   
   
       7 . An intravenous formulation comprising: 
 (a) an opiate destruction-inhibiting amount of at least one substance which inhibits the enzymatic destruction of neuropeptidyl opiate, said substance being selected from the group consisting of amino acids, peptides, and structural analogues or derivatives thereof:    b) a neurotransmitter synthesis-promoting amount of at least one neurotransmitter precursor selected from the group consisting of dopamine precursors L-Tyr, L-Phe and L-dopa, serotonin precursors L-Trp and 5-hydroxytryptophan, and gamma amino butyric acid (GABA) precursors L-glutamine, L-glutamic acid, and L-glutamate; and    c) a tryptophan concentration enhancing amount of chromium picolinate or chromium nicotinate; 
 wherein the amount of said substance and said neurotransmitter precursor and said chromium compound being effective in reducing a subject's RDS behaviors.  
   
   
   
       8 . An intravenous formulation of claims  1  or  5  comprising about 16 to 500 mg of D-Phenylalanine.  
   
   
       9 . An intravenous formulation comprising ethanol at least one of: L-Phenylalanine, L-Tyrosine, L-Tryptophan, L-Glutamine, L-5-Hydroxytryptophan, Pyrodoxal Phosphate, Chromium Picolinate, Chromium Nicotinate, Tyrosine-D-Ar,  Rhodiola Rosea , and Huberzine A.  
   
   
       10 . The intravenous formulation of  claim 9  comprising at least one of: 5 to 5,000 mg of L-Phenylalanine, 5 to 5, 000 mg of L-Tyrosine, 9 to 90,000 mg L-Tryptophan, 0.9 to 9,000 mg L-5-Hydroxytryptophan, and 3 to 30,000 mg L-Glutamine.  
   
   
       11 . The intravenous formulation of  claim 9  comprising about 1500 mg L-Phenylalanine, about 900 mg L-Tyrosine, about 500 mg L-Tryptophan, about 300 mg L-Glutamine, about 20 mg of Pyrodoxal Phosphate and about 400 ug Chromium Picolinate or Chromium Nicotinate.  
   
   
       12 . The intravenous formulation of  claim 9  comprising about 1500 mg L-Phenylalanine, about 900 mg L-Tyrosine, about 500 mg L-Tryptophan, about 300 mg L-Glutamine, about 20 mg of Pyrodoxal Phosphate, about 400 ug Chromium Picolinate or Chromium Nicotinate, and about 15 ug of Tyrosine-D-Arg.  
   
   
       13 . The intravenous formulation of  claim 9  comprising about 1500 mg L-Phenylalanine, about 900 mg L-Tyrosine, about 500 mg L-Tryptophan, about 300 mg L-Glutamine, about 20 mg of Pyrodoxal Phosphate, about 400 ug Chromium Picolinate or Chromium Nicotinate, about 15 ug of Tyrosine-D-Ar, and about 25 mg  Rhodiola Rosea , and about 10 ug Huberzine A.  
   
   
       14 . The intravenous formulation of  claim 9  comprising about 1500 mg L-Phenylalanine, about 900 mg L-Tyrosine, about 500 mg L-Tryptophan, about 300 mg L-Glutamine, about 20 mg of Pyrodoxal Phosphate, about 400 ug Chromium Picolinate or Chromium Nicotinate, about 15 ug of Tyrosine-D-Arg, about 25 mg  Rhodiola Rosea , about 10 ug Huberzine A, and about 10% ethanol.